Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Kite Pharma Inc (NASDAQ:KITE)

98.05
Delayed Data
As of 4:00pm ET
 -2.38 / -2.37%
Today’s Change
39.82
Today|||52-Week Range
103.65
+118.67%
Year-to-Date
Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger
Jun 22 / Zacks.com - Paid Partner Content
Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More
Jun 21 / Zacks.com - Paid Partner Content
4 Stocks & ETFs to Buy on Clovis' Positive Drug Data
Jun 21 / Zacks.com - Paid Partner Content
Cancer treatment: scaling up a vein-to-vein solution
Jun 12 / FT.com - Paid Partner Content
Fresh Capital to Be Injected into Biotech Stocks: 5 Must-Buys
Jun 21 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close100.43
Today’s open101.00
Day’s range97.70 - 103.65
Volume1,791,283
Average volume (3 months)1,635,860
Market cap$5.7B
Dividend yield--
Data as of 4:00pm ET, 06/27/2017

Growth & Valuation

Earnings growth (last year)-134.33%
Earnings growth (this year)-51.28%
Earnings growth (next 5 years)--
Revenue growth (last year)+28.46%
P/E ratioNM
Price/Sales98.98
Price/Book11.75

Competitors

 Today’s
change
Today’s
% change
BIVVBioverativ Inc-0.51-0.84%
BLUEbluebird bio Inc-4.20-3.78%
TECHBio-Techne Corp-0.43-0.36%
NBIXNeurocrine Bioscienc...-1.75-3.70%
Data as of 4:00pm ET, 06/27/2017

Financials

Next reporting dateAugust 16, 2017
EPS forecast (this quarter)-$1.91
Annual revenue (last year)$22.2M
Annual profit (last year)-$267.1M
Net profit margin-1,204.65%

Profile

Sector
Health Technology
Industry
Biotechnology
Executive Chairman, President &
CEO
Arie S. Belldegrun
Chief Operating Officer
Cynthia M. Butitta
Corporate headquarters
Santa Monica, California

Forecasts